Sailong Pharmaceutical Group Co.,Ltd. (SHE:002898)
China · Delayed Price · Currency is CNY 11.18
-0.10 (-0.89%)
At close: Feb 13, 2026
SHE:002898 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 242.33 | 261.06 | 303.51 | 261.14 | 244.05 | 117.59 |
Other Revenue | 2.51 | 2.51 | 7.12 | 3.05 | 3.03 | 3.09 |
| 244.84 | 263.57 | 310.63 | 264.19 | 247.08 | 120.68 | |
Revenue Growth (YoY) | -19.46% | -15.15% | 17.58% | 6.93% | 104.73% | -58.88% |
Cost of Revenue | 214.22 | 176.78 | 171.11 | 127.84 | 86.71 | 46.31 |
Gross Profit | 30.62 | 86.78 | 139.52 | 136.35 | 160.37 | 74.37 |
Selling, General & Admin | 57.98 | 81.29 | 106.81 | 142.59 | 157.22 | 124.76 |
Research & Development | 20.18 | 24.51 | 27.53 | 23.5 | 21.41 | 25.67 |
Other Operating Expenses | 4.56 | 3.36 | 3.2 | 4.93 | 4.76 | 2.96 |
Operating Expenses | 81.26 | 109.5 | 126.14 | 178.8 | 186.36 | 151.03 |
Operating Income | -50.64 | -22.72 | 13.38 | -42.44 | -25.99 | -76.65 |
Interest Expense | -7.17 | -6.73 | -6.91 | -8.08 | -6.6 | -5.72 |
Interest & Investment Income | 0.16 | 0.43 | 0.68 | 1.26 | 9.81 | 0.9 |
Other Non Operating Income (Expenses) | 0.14 | 0.28 | 1.05 | -0.69 | -0.65 | -0.5 |
EBT Excluding Unusual Items | -57.51 | -28.73 | 8.21 | -49.96 | -23.43 | -81.97 |
Gain (Loss) on Sale of Investments | -0.08 | - | 7.59 | 17.09 | 6.73 | 33.56 |
Gain (Loss) on Sale of Assets | -0.5 | -0.9 | 1.06 | 0.46 | -0.01 | -0 |
Asset Writedown | -13.56 | -6.59 | -0.01 | 0.02 | -0.13 | -1.03 |
Other Unusual Items | 0.89 | 1.3 | 5.52 | 2.71 | 3.07 | 0.62 |
Pretax Income | -70.76 | -34.92 | 22.36 | -29.67 | -13.77 | -48.83 |
Income Tax Expense | -0.91 | -1.77 | 12.82 | 7.64 | 9.57 | 18.4 |
Net Income | -69.85 | -33.15 | 9.53 | -37.31 | -23.34 | -67.22 |
Net Income to Common | -69.85 | -33.15 | 9.53 | -37.31 | -23.34 | -67.22 |
Shares Outstanding (Basic) | 176 | 176 | 176 | 176 | 176 | 176 |
Shares Outstanding (Diluted) | 176 | 176 | 176 | 176 | 176 | 176 |
Shares Change (YoY) | 0.11% | 0.07% | -0.06% | -0.01% | 0.01% | 0.04% |
EPS (Basic) | -0.40 | -0.19 | 0.05 | -0.21 | -0.13 | -0.38 |
EPS (Diluted) | -0.40 | -0.19 | 0.05 | -0.21 | -0.13 | -0.38 |
Free Cash Flow | -76.1 | -73.53 | 5.13 | -9.82 | 3.99 | -63.88 |
Free Cash Flow Per Share | -0.43 | -0.42 | 0.03 | -0.06 | 0.02 | -0.36 |
Dividend Per Share | - | - | 0.020 | - | - | - |
Gross Margin | 12.51% | 32.93% | 44.91% | 51.61% | 64.91% | 61.63% |
Operating Margin | -20.68% | -8.62% | 4.31% | -16.06% | -10.52% | -63.52% |
Profit Margin | -28.53% | -12.58% | 3.07% | -14.12% | -9.45% | -55.70% |
Free Cash Flow Margin | -31.08% | -27.90% | 1.65% | -3.72% | 1.61% | -52.93% |
EBITDA | -19.54 | 9.15 | 46.28 | -9.35 | 5.59 | -47.36 |
EBITDA Margin | -7.98% | 3.47% | 14.90% | -3.54% | 2.26% | -39.24% |
D&A For EBITDA | 31.1 | 31.87 | 32.9 | 33.09 | 31.58 | 29.29 |
EBIT | -50.64 | -22.72 | 13.38 | -42.44 | -25.99 | -76.65 |
EBIT Margin | -20.68% | -8.62% | 4.31% | -16.06% | -10.52% | -63.52% |
Effective Tax Rate | - | - | 57.36% | - | - | - |
Revenue as Reported | 244.84 | 263.57 | 310.63 | 264.19 | 247.08 | 120.68 |
Advertising Expenses | - | 0.48 | 0.37 | 0.16 | 0.84 | 0.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.